Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

Monday’s trading has closed, but SGYP is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 3:59pm ET
 +0.20 / +3.28%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of drugs to treat gastrointestinal disorders and diseases. Its lead product candidate includes plecanatide a phase 3 guanylate cyclase C, or GC-C, receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of individuals worldwide. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY.

Contact Information

Synergy Pharmaceuticals, Inc.
420 Lexington Avenue
New York New York 10170
P:(212) 297-0020
Investor Relations:



Other institutional28.44%
Mutual fund holders18.40%
Individual stakeholders1.44%

Top Executives

Gary S. JacobChairman, President & Chief Executive Officer
Laura BarrowSenior Vice President-Clinical Operations
Bernard F. DenoyerSecretary, SVP-Finance & Head-Investor Relations
Kunwar ShailubhaiChief Scientific Officer
Patrick H. GriffinChief Medical Officer & Executive Vice President